GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Return-on-Tangible-Asset

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Return-on-Tangible-Asset : -137.46% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Coeptis Therapeutics Holdings's annualized Net Income for the quarter that ended in Mar. 2024 was $-12.00 Mil. Coeptis Therapeutics Holdings's average total tangible assets for the quarter that ended in Mar. 2024 was $8.73 Mil. Therefore, Coeptis Therapeutics Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -137.46%.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Return-on-Tangible-Asset or its related term are showing as below:

COEP' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3052   Med: -446.26   Max: -266.05
Current: -285.42

During the past 4 years, Coeptis Therapeutics Holdings's highest Return-on-Tangible-Asset was -266.05%. The lowest was -3052.00%. And the median was -446.26%.

COEP's Return-on-Tangible-Asset is ranked worse than
93.94% of 1550 companies
in the Biotechnology industry
Industry Median: -40.065 vs COEP: -285.42

Coeptis Therapeutics Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Return-on-Tangible-Asset Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-3,052.00 -380.67 -511.84 -266.05

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -603.22 -380.18 -599.83 -241.58 -137.46

Competitive Comparison of Coeptis Therapeutics Holdings's Return-on-Tangible-Asset

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Return-on-Tangible-Asset falls into.



Coeptis Therapeutics Holdings Return-on-Tangible-Asset Calculation

Coeptis Therapeutics Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-21.267/( (7.916+8.071)/ 2 )
=-21.267/7.9935
=-266.05 %

Coeptis Therapeutics Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-12.004/( (8.071+9.394)/ 2 )
=-12.004/8.7325
=-137.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Coeptis Therapeutics Holdings  (NAS:COEP) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Coeptis Therapeutics Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Headlines